A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Officials said over 71,000 Oklahomans are currently living with Alzheimer's disease. Nationally, that number is approaching 7 ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Fortunately, the FDA has approved antipsychotic treatments that help manage these destructive symptoms, and more are in ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Researchers have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer's genesis and progression. The proteins were gathered from cerebrospinal ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The preprint was posted on Research Square and had not been peer-reviewed ...

Can large national health plans make an impact in reducing prescribing of high-risk medications to people with Alzheimer's disease or related dementias by mailing patients, caregivers and their ...